research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
Search
for
Sort by
Research
420-450 / 1000+ results research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
Amivantamab treatment often causes skin issues that can affect quality of life and treatment continuation.
research Valproic acid – induced Pleuro-pericardial Effusion
Valproic acid can rarely cause fluid buildup around the lungs and heart.
research Citalopram and finasteride with the lot number FI0510058-A have been voluntarily recalled by Greenstone, after a labelling error
research Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research Valproic Acid (Depakene)
Valproic acid is effective for various seizures, but may cause temporary side effects like drowsiness and stomach issues.
research REV7: a small but mighty regulator of genome maintenance and cancer development
REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.
research Actualización en plasma rico en plaquetas
More research is needed to standardize and prove the effectiveness of platelet-rich plasma treatments.
research Risk of finasteride-related suicidal ideation
research O impacto da COVID-19 no ciclo menstrual: uma perspectiva geral
The combination tablet of finasteride and doxazosin works the same as taking each drug separately.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research Дослідження ПРОСПЕКТ IV (ПРОСтамол: ПЕрспективи Комбінованої Терапії) у хворих на доброякісну гіперплазію передміхурової залози
"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research A liquid chromatography/tandem mass spectrometry method for determination of aristolochic acid‐I in rat plasma
A reliable method was developed to measure aristolochic acid-I in rat blood.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients
FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.
research Adverse Effects and Drug Interactions of Biologic Agents
Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
research Worldwide Clinical and Real-World Exposure to Baricitinib
Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia
Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
research Sexual adverse events-related to dutasteride e finasteride: analysis of real-life data from Eudra-Vigilance database
research BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF FINASTERIDE, TADALAFIL, AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RAT PLASMA BY USING LC-MS/MS
A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
research Nurses' Drug Alert
Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.